NO platform allows you to synthesize original hybrid molecules consisting of pharmaceutically active compounds (API), prostaglandins (PG) and nitric oxide donors (NO-donors)
Main News
* Gurus successfully completed preclinical trials of asthma treatment drug * Magazine Kommersant published an article about promising multifunctional drug candidates of Gurus BioPharm * Gurus raises $0.7M for preclinical trials of a drug for asthma


Gurus BioPharm LLC (“Gurus”) is a research and investment company developing innovative drugs. We finance and develop groundbreaking Russian biopharmaceutical innovations from the early stages to commercialization at the global market. We provide an opportunity for private investors to co-invest with us in cutting-edge innovations that can change current standards of healthcare in the world.

We develop innovative drugs to restore the human health and quality of life in chronic diseases. We believe in the great potential of the Russian science and contribute to the creation of a new Russian innovative economy. We help scientists to turn their idea into a drug. We offer the projects in the most profitable and fastest growing industry in the world for investors. Our business unites these aspirations.

How we work
Gurus selects advanced Russian biopharmaceutical innovations that have the potential to sufficiently change current standards of healthcare in the world. We created an efficient mechanism of developing projects starting from early stage when the new idea just showed first promising results in the lab. Advanced expertise, deep involvement in R&D process, harmonious collaboration between Gurus and inventors as a one team, capital-efficient mechanisms that we created make possible for Gurus to develop efficiently very early stage projects, when it is the most difficult for the project to prove its potential and get venture capital for further development.
Once the project is selected, Gurus invests in the project to prepare it for preclinical studies. For this joined team of Gurus and inventors performs tests on animal models and strengthening intellectual property. Then Gurus invests a part of venture capital itself and raise other part of capital outside to run preclinical and clinical trials. Gurus team executes and manages all stages of drug development. We run drug development in line with GLP, GCP standards in partnership with local and foreign research institutes and contract research organizations (CRO). For some projects we create R&D alliances with pharmaceutical company or collaborate with venture fund for co-investments.
When proof of concept (POC) is shown in clinical trials, Gurus team plans to exit the project through M&A or out-licensing or may decide to develop it further by yourself

Gurus BioPharm was founded in 2011 by enthusiasts which have industrial, scientific and commercial experience, and who dreamed of creating a mechanism for commercializing Russian biopharmaceutical projects.
In 2005 Igor Teterin founded a consulting company Gurus which started to performed M&A transactions and capital raising for small and middle companies, later Gurus started to lead consulting projects for pharmaceutical companies on valuation of drug candidates, due diligence, business valuation, and marketing research of the pharmaceutical market.
In 2008 Igor Lyubimov completed work at the government research institute and continued his career with private life sciences investment firms and pharmaceutical contract research organizations on managerial positions.
In late 2010, our ways crossed and we united into a one team.